Acceleron to Webcast Third Quarter 2019 Operating and Financial Results on November 6, 2019
29 Octubre 2019 - 5:00AM
Business Wire
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host
a webcast and conference call on Wednesday, November 6, 2019 at
10:00 a.m. EST to discuss its third quarter 2019 operating and
financial results.
The webcast will be accessible under "Events &
Presentations" in the Investors/Media page of the company's website
at www.acceleronpharma.com. Individuals can participate in the
conference call by dialing 877-312-5848 (domestic) or 253-237-1155
(international) and refer to the “Acceleron Third Quarter 2019
Earnings Call.”
The archived webcast will be available for replay on the
Acceleron website approximately two hours after the event.
About Acceleron
Acceleron is a clinical-stage biopharmaceutical company
dedicated to the discovery, development, and commercialization of
therapeutics to treat serious and rare diseases. The Company's
leadership in the understanding of TGF-beta superfamily biology and
protein engineering generates innovative compounds that engage the
body's ability to regulate cellular growth and repair.
Acceleron focuses its research and development efforts in
hematologic, neuromuscular, and pulmonary diseases. In hematology,
the Company and its global collaboration partner, Celgene, are
developing luspatercept for the treatment of chronic anemia in
myelodysplastic syndromes, beta-thalassemia, and myelofibrosis.
Acceleron is also advancing its neuromuscular program with ACE-083,
a locally-acting Myostatin+ agent in Phase 2 development for
Charcot-Marie-Tooth disease and is conducting a Phase 2 pulmonary
program with sotatercept in pulmonary arterial hypertension.
For more information, please visit acceleronpharma.com/. Follow
Acceleron on Social Media: @acceleronpharma and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191029005157/en/
Acceleron Pharma Inc. Investors: Todd James, IRC, 617-649-9393
Vice President, Investor Relations and Corporate Communications
Ed Joyce, 617-649-9242 Director, Investor Relations
Media: Matt Fearer, 617-301-9557 Director, Corporate
Communications
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024